A Phase 2a Open Label, Single Arm Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Sponsors

Lead sponsor: Stero Biotechs Ltd.

Source Stero Biotechs Ltd.
Brief Summary

Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with corticosteroids

Detailed Description

Patients will be included if they are in stable remission with a prednisone at the lower stable dose to maintain remission with or without azathioprine , Budesonide with or without azathioprine or azathioprine alone for at least 24 months.

Patient will be switch from standard of care to treatment with Cannabidiol for 12 months. They will receive increasing doses of Cannabidiol over a period of one month. Dosage will start at 25 mg Cannabidiol twice a day and will be increased every seven days, if no side effects are observed, to 50 mg, 100 mg and finally to 150 mg Cannabidiol twice a day respectively, as detailed below.

At the end of this month, if the 150 mg twice a day dose level is deemed safe for one week, the standard of care will be stopped at once and patients will continue receiving only Cannabidiol 150 mg twice a day for an additional period of 11 months.

The patient will be offered to undergo liver biopsy in the screening period to prove histological remission along with the biochemical remission (not mandatory for inclusion).

After 12 months of treatment with Cannabidiol all patient will undergo liver biopsy for confirmation of histological remission and then the treatment will be stopped as for physician decision and guidelines of treatment of autoimmune hepatitis disease.

In any case of flare defined as elevation in liver enzymes and immunoglobulins in consecutive blood test the patient will reintroduced for standard of care treatment at a dosage as of investigator decision and the Cannabidiol will be discontinued.

The patient will be withdrawn from the study but will continue follow up until returning to stable inactive disease as define as normalization of liver enzymes and immunoglobulin level in consecutive blood tests.

Overall Status Recruiting
Start Date February 7, 2019
Completion Date January 2021
Primary Completion Date January 2021
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Proportion of patients with biochemical and histological remission 12 month
Number of patients who experience Cannabidiol relates adverse events 12 month
Proportion of patients with flare up of hepatitis 12 month
Enrollment 15
Condition
Intervention

Intervention type: Drug

Intervention name: Cannabidiol

Description: Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally

Arm group label: Sintetic Cannabidiol

Eligibility

Criteria:

Inclusion Criteria:

1. Patients with histologically confirmed chronic hepatitis

2. Age ≥18 years

3. Subject able to provide written informed consent

4. Stable disease for 24 months

5. Currently being administered prednisone (with or without azathioprine) therapy at the lower stable dose to maintain remission or Budesonide (with or without azathioprine) therapy at the lower stable dose to maintain remission or azathioprine alone.

6. ALT ≤ 30 U/L in men and ≤19 U/L in women

7. IgG < 1450 mg/dL

8. Non-pregnant women (via negative pregnancy test) and women with no intention to become pregnant during the term of the trial or three months after cessation of CBD treatment

Exclusion Criteria:

1. Viral Hepatitis (HAV, HBV, HCV)

2. HIV

3. Serious psychiatric or psychological disorders

4. Active consumption of illicit drugs including cannabis or derivatives (at least 1 month before study start)

5. Overlap disease with Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

6. IgG4 related Autoimmune Hepatitis

7. Transplant patients

8. Patients with significant cardiac, respiratory or active malignance disease comorbidities.

9. Renal comorbidity: eGFR < 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)

10. Cirrhosis

11. Patients treated with corticoids for other indication except Autoimmune Hepatitis

12. Patient that are taking immunomodulatory medications for other indication

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Overall Contact

Last name: Sari Sagiv

Phone: 972528594444

Phone ext: 972528594444

Email: [email protected]

Location
facility status contact Belinson Medical Center Assaf Issachar, Dr. [email protected]
Location Countries

Israel

Verification Date

October 2019

Responsible Party

Responsible party type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Arm group label: Sintetic Cannabidiol

Arm group type: Experimental

Description: Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day

Patient Data Undecided
Study Design Info

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov